[{"orgOrder":0,"company":"Bionomics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$526.0 million","upfrontCash":"$20.0 million","newsHeadline":"Bionomics Announces Update on the \u03b17 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Bionomics"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Alterity Therapeutics"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Meeting with US FDA Provides Development Pathway for ATH434","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Alterity Therapeutics"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Independently Confirms and Extends Laboratory Findings and Expands Safety Profile of ATH434","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Alterity Therapeutics"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity to Present at the 7th International Congress of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Alterity Therapeutics"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Granted a New US Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Alterity Therapeutics"},{"orgOrder":0,"company":"PharmAust","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND \/ ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmAust"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
PPL-1 (monepantel) is a positive allosteric modulator of DEG-3/DES-2 type nicotinic acetylcholine receptors (nAChRs). It is being evaluated for the treatment of motor neurone disease & amyotrophic lateral sclerosis.
Under the collaboration, MK-4334, a novel clinical candidate was developed by MSD and derived from Bionomics’ original α7 nAChR PAM candidate (BNC375) for the treatment of cognitive disorders like Alzheimer’s Disease.
The scientific investigation of ATH434, along with the results from the Phase 2 study, will augment the development and optimization of novel compounds expected to emerge from the new patent.
Alterity will be presenting further information on ATH434. The new results to be presented include data on blood pressure following change in body position, which demonstrate that ATH434 does not lower blood pressure when subjects move to the standing position.
The new data, from an experiment testing ATH434 in an animal model of Multiple System Atrophy (MSA), independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor performance.
The pre-IND (Investigational New Drug) meeting was to obtain input on the clinical development plan for ATH434, including feedback on the Phase 2 study design.
The abstract, presentation and article share findings from Alterity's completed Phase 1 trial of leading drug candidate ATH434, which evaluated the safety, tolerability, and pharmacokinetics in healthy adult and older adult volunteers.